Abstract: The present invention relates to the use of human anti-inflammatory peptides in the inhalatory treatment of inflammatory pulmonary diseases. The invention in particular relates to the use of vasoactive intestinal peptide, C-type natriuretic peptide, B-type natriuretic peptide, pituitary adenylate cyclase-activating peptide, adrenomedullin, alpha-melanocyte stimulating hormone, relaxin and Interferon gamma for said purposes. Advantageous features of an aerosol containing such a human anti-inflammatory peptide and a method for producing said aerosol are disclosed. The present invention further relates to a kit for inhalatory treatment of inflammatory pulmonary diseases. One aspect relates to treatment of CoViD-19 related ARDS.
Type:
Application
Filed:
January 29, 2021
Publication date:
April 6, 2023
Applicant:
ADVITA LIFESCIENCE GMBH
Inventors:
Holger KLAPPROTH, Dorian BEVEC, Björn Christian FRYE, Joachim MÜLLER-QUERNHEIM, Jörg VON WEGERER, Wolfgang HOPPE, Marc A. KESSEMEIER